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categories: genes with relative fold-change of mRNA less than 10
fold (A), genes with relative fold-change of mRNA between 10 and
100 fold (B), genes with relative fold-change of mRNA more than
100 fold (C).
Conclusions: These results indicated that resistin, the adipocyte-
derived cytokine, could be an important link between obesity and
osteoarthritic (OA) joint disease. Resistin is a proinﬂammatory
and destructive mediator of joint inﬂammation in human joint, and
might be considered as a potential therapeutical target in joint
degenerative diseases such as OA.
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Purpose: Although osteoarthritis (OA) was originally described
as a noninﬂammatory arthropathy, inﬂammatory responses in syn-
ovium and cartilage may contribute to disease progression. Inﬂam-
mation is caused by direct biomechanical perturbation or reaction
to cartilage matrix degradation. Recent evidence has emerged for
a role of the Hoffa’s fat pad in the development and progression of
OA by the secretion of pro-inﬂammatory cytokines. The Hoffa’s fat
pad is located in the knee, intraarticular and extrasynovial, under
the patella.
Peroxisome Proliferator-Activated Receptorα (PPARα) is a mem-
ber of class I nuclear receptor superfamily of ligand-dependent
transcription factors. Anti-inﬂammatory effects of PPARα agonists
have been described in adipose tissue, liver, blood vessels, kidney,
macrophages and mesangial cells. We hypothesized that addition
of synthetic PPARα agonist Wy-14643 exerts anti-inﬂammatory
effects in OA joint tissues.
Methods: Explants of synovium (n=9), cartilage (n=9) and Hoffa’s
fat pad (n=10) were obtained from OA patients that underwent total
knee arthroplasty. Explants were cultured in DMEM-high glucose
with ITS, with(out) 100 μM PPARα agonist. 10 ng/ml Il-1β was
added as a pro-inﬂammatory stimulus. Gene expression analysis
was performed on cartilage explants (MMP1, MMP3, MMP13, ag-
grecan, collagen type II) and on synovium explants (MMP1, MMP3,
MMP13, Il-1β). The culture supernatant of cartilage and synovium
samples was analysed for NO production. Supernatant of cartilage
was analysed for GAG release. The culture supernatant of Hoffa’s
fat pad was analysed with ELISA for leptin, adiponectin, resistin,
MCP-1, TNFα, Il-1β, Il-6, Il-4 and Il-10. A decrease or increase
was deﬁned as more than 25 % of the control value. Results were
analysed with non-parametric tests.
Results: Addition of PPARα agonist decreased mRNA expression
of cartilage with 76 % for MMP1 (p=0.12), 68 % for MMP3 (p=0.02)
and 87 % for MMP13 (p=0.01). Addition of IL-1β decreased
collagen type II gene expression a 15-fold. Addition of the PPARα
agonist decreased this expression even more with 49% (p=0.02).
Aggrecan mRNA expression was not inﬂuenced by the PPARα
agonist. NO production of cartilage showed a trend towards a
decrease by the addition of PPARα agonist. The release of GAG
in cartilage culture supernatant was lower after addition of 100 μM
PPARα agonist (p=0.06).
A trend towards decrease could be observed for MMP1, MMP3
and MMP13 after adding PPARα agonist. Il-1β mRNA expression
and NO production by synovium was not inﬂuenced by the PPARα
agonist.
In culture supernatant of Hoffa’s fat pad, MCP-1 (p=0.01), Il-4
(p=0.03) and Il-10 (p=0.03) were decreased after adding PPARα
agonist. 7 donors showed a decrease and 2 an increase for TNFα
production (p=0.18). Leptin, resistin and Il-1β showed a trend
towards more donors with a decrease. Adiponectin and Il-6 were
not inﬂuenced.
Conclusions: Addition of 100 μM PPAR α agonist Wy-14643 de-
creased IL-1β induced MMP gene expression, NO production and
GAG release in cartilage and had an effect on collagen type II,
but not on aggrecan production. A non signiﬁcant decrease was
seen for MMP expression in synovium. The production of pro- and
anti-inﬂammatory cytokines by Hoffa’s fat pad was decreased by
adding 100 μM PPAR α agonist. In general, the use of PPAR α
agonist Wy-14643 showed promising results in inhibiting inﬂam-
matory processes in OA joint tissues. The use of these synthetic
ligands for treatment of OA should be further explored.
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Purpose: It has been suggested that many cases of primary hip
OA are actually caused by mild morphological variations in the
shape of the hip. Interestingly, genes that have been found to
affect susceptibility for OA such as FRZB, GDF5 and DIO2, are
involved in endochondral ossiﬁcation and regulate the process of
skeletal formation.
In this study, we have quantiﬁed the shape of the hip in sibling
pairs of the GARP study, who have symptomatic OA at multiple
joint locations. We estimated familial aggregation of hip shape and
investigated whether shape is affected by the genetic variation at
the OA susceptibility genes.
Methods: A Statistical Shape Model was created of the shape
of the proximal femur and pelvis of radiographs of the hips of
sibling pairs of the GARP study. The method results in a set
of independent modes that together quantitatively describe the
total shape, while each mode separately describes a speciﬁc
characteristic of the shape. This preliminary data concerns 74
sibling pairs (148 subjects), of which 29 subjects had radiographic
signs of hip OA (KL>1). Familial aggregation (heritability) of shape
was estimated from the variance within and between siblings.
Associations between shape and SNPs of the FRZB, GDF5 and
DIO2 genes were tested using mixed model regression with height,
gender, age, BMI, and OA status (KL>1 for 0, 1 or 2 hips) as
co-variables. In these analyses we modeled familial and left and
right hip dependencies through random effect variables.
Results: 5 out of 30 modes showed signiﬁcant familial aggregation
describing over 60% of the total variation in shape. OA status
associated signiﬁcantly with femurs with a stocky appearance
(mode 6, p=0.03), a short superior neck (mode 11, p=0.002)
and a small offset between superior neck and head (mode 17,
p=0.035). It is unclear whether these associations are the result
of the OA disease process or point to a factor underlying the OA
process. Modes 5 (p=0.012) and 16 (p=0.004) showed a dose
response association with respectively DIO2 OA susceptibility
SNPs rs225014 and rs12885300. Both modes are descriptors of
acetabular shape. Mode 3 associated signiﬁcantly (p=0.002) with
the FRZB SNP rs388326 and describes the slenderness of femur
and pelvis (see Figure 1 for modes 3 and 5). No associations were
found for GDF5.
Conclusions: These initial analyses showed that a large part of
the variation in hip shape is attributable to familial aggregation
(>60%) which reﬂects both shared genetic and environmental
